Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viva Biotech HoldingsFRA:VB0 -8.22%47 Debt-to-EBITDA is 2.48 as of Dec. 2025, which is 1450% above its 10-year median of 0.16. GuruFocus rates FRA:VB0 with a GF Score™ of 47/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 291 Biotechnology companies, Viva Biotech Holdings ranks worse than 62.89% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Viva Biotech Holdings's Debt-to-EBITDA or its related term are showing as below:
FRA:VB0'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -31.71 Med: 0.16 Max: 5.74
Current: 2.36
During the past 10 years, the highest Debt-to-EBITDA Ratio of Viva Biotech Holdings was 5.74. The lowest was -31.71. And the median was 0.16.
FRA:VB0's Debt-to-EBITDA is ranked worse than 62.89% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs FRA:VB0: 2.36
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Viva Biotech Holdings Debt-to-EBITDA Related Terms
Viva Biotech Holdings Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Viva Biotech Holdings (FRA:VB0) has a Debt-to-EBITDA of 2.48 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Viva Biotech Holdings. This is 1450% above median its historical median of 0.16. According to the industry distribution chart, Viva Biotech Holdings ranks #183 out of 291 companies in the Biotechnology industry, placing it in the top 62.9%.
Is Viva Biotech Holdings' Debt-to-EBITDA too high?
Viva Biotech Holdings' current Debt-to-EBITDA of 2.48 is 1450% above median its 10-year median of 0.16. The Biotechnology industry median Debt-to-EBITDA is 1.14. Viva Biotech Holdings' value of 2.48 is 117.5% above this industry median. Based on the distribution chart, Viva Biotech Holdings ranks #183 out of 291 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Viva Biotech Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #183 out of 291 companies for Debt-to-EBITDA. This places Viva Biotech Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. Viva Biotech Holdings' value of 2.48 is 117.5% above this benchmark. While the company's 10-year median is 0.16 vs. the industry median of 1.14, Viva Biotech Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viva Biotech Holdings's current Debt-to-EBITDA of 2.48 is 117.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Viva Biotech Holdings. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viva Biotech Holdings's current Debt-to-EBITDA is 2.48, which is 1450% above median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.13 — trading 67.5% above its estimated fair value. The current Debt-to-EBITDA is 2.48, which is 1450% above median its 10-year median of 0.16 and 117.5% above the Biotechnology industry median of 1.14. Viva Biotech Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Debt-to-EBITDA is 2.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.13 is trading 67.5% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
Debt-to-EBITDA: 2.48 (1450% above median its 10-year median of 0.16)
GF Value™: €0.08 vs. price of €0.13 (67.5% above fair value)
Industry Position: 117.5% above the Biotechnology median (#183 of 291)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
47GF Score
Get the complete analysis for FRA:VB0
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
